ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

N/AUnknownNCT02946216

First People's Hospital of Hangzhou200 enrolled

Overview

The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Non-small Cell Lung Cancer Stage III Non-Small-Cell Lung Cancer Metastatic Adenocarcinoma of Lung EGFR Wildtype

Interventions

ctDNA analysisGENETIC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed stage IIIB/IV NSCLC; * Histologically confirmed adenocarcinoma; * EGFR-wildtype NSCLC; * Provision of blood (plasma) sample for ctDNA testing; * Patient must be able to comply with the protocol; * Provision of blood (plasma) sample for ctDNA testing; Exclusion Criteria: * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease); * Histologically confirmed small cell lung cancer or other metastatic tumors; * Patient with no histologic or cytological diagnosis;

Locations (1)

Hangzhou First People's Hospital, Nanjing Medical University

Hangzhou, Zhejiang, China

Outcomes

Primary Outcomes

Proportion of patients with ALK/ROS1/MET mutations detected by single molecule amplifcation and re-sequencing technology (cSMART)

The investigators will describe the proportion of ALK/ROS1/MET mutations on ctDNA detected by cSMART in patients with non-small cell lung cancer (NSCLC)

Time frame: up to 2 years

Proportion of patients with ALK/ROS1/MET mutations detected by single molecule amplifcation and re-sequencing technology (cSMART) after crizotinib resistance

The investigators will describe the proportion of ALK/ROS1/MET mutations on ctDNA detected by cSMART in patients with non-small cell lung cancer (NSCLC) after crizotinib resistance

Time frame: up to 2 years

Central Contacts

Shenglin Ma, M.D

CONTACT

057156007908 mashenglin@medmail.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.